Lurbinectedin

Phase 2

Jazz Pharmaceuticals plc (JAZZ)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '26

JAZZPhase 2$15.3B

Lurbinectedin Phase 2 Est. Readout

Lurbinectedin• Refractory Ewing Sarcoma60

Q4 2026~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Refractory Ewing Sarcoma

View Full Landscape

Drug Information

Target Indication

Refractory Ewing Sarcoma

Clinical Trial

NCT05734066

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/29/2026

Zepzelca

Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

JAZZ

Jazz Pharmaceuticals plc

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

NabiximolsPhase 3

Pain

SativexPhase 3